Table 1.
Selection Criteria in Prospective Recent Myopia Control Clinical Trials
| Author, Year | Intervention | SER (Min to Max), D | Cycloplegia | Ast Limit, D | Aniso Limit, D | VA Min | Age, Min to Max, y |
|---|---|---|---|---|---|---|---|
| Bao et al. 2022101 | Spectacles (highly aspherical lenslets or slightly aspherical lenslets) |
−4.75 to −0.75 | Y | 1.50 | 1.00 | 20/22 (0.05 logMAR) | 8 to 13 |
| Chamberlain et al. 2022103 | SCL (concentric dual zone) | −4.00 to −0.75 | Y | 0.75 | 1.00 | 20/25 | 8 to 12 |
| Chan et al. 2022108 | 0.01% atropine | −5.00 to −0.50 | Y | 1.00 | NR | 20/20 | 7 to 10 |
| Chuang et al. 2021109 | 0.05% atropine (concentration increased if >0.50 D 6-month progression) | −0.50 to −5.00 | Y | 2.00 | NR | NR | NR (figures show ∼5 to 8) |
| Cui et al. 2021110 | 0.02% or 0.01% atropine | −6.00 to −1.25 | Y | 2.00 | 1.00 | 16/20 (20/25) | 6 to 14 |
| Fu et al. 2021111 | 0.01% or 0.02% atropine | −6.00 to −1.25 | Y | 2.00 | 1.00 | 20/25 | 6 to 14 |
| Han et al. 2021125 | Auricular acupressure | −0.50 to +0.50 | Y | NR | NR | 20/25 (from decimal) | 8 to 9 |
| Hieda et al. 2021104 | SCL (multifocal) | −6.00 to −1.00 | Y | 1.50 | 1.50 | 20/20 | Grades 1 to 6 in school (Japan) |
| Hieda et al. 2021112 | 0.01% atropine | −6.00 to −1.00 | Y | 1.50 | 1.50 | 20/20 | 6 to 12 |
| Jakobsen and Moller 2022107 | ortho-k | −4.75 to −0.50 (sphere) | Y | 2.50 | 1.50 | 78 ETDRS letters | 6 to 12 |
| Jiang et al. 202274 | Low-level red light therapy | −5.00 to −1.00 | Y | 2.50 | 1.50 | 20/20 | 8 to 13 |
| Jones et al. 2022119 | 0.01% atropine with multifocal SCL | −5.00 to −0.50 (spherical component) | Y | 1.00 | 2.00 | 20/25 | 7 to 11 |
| Kong et al. 2021120 | 0.01% atropine plus auricular acupoint stimulation | −6.00 to +0.50 | Y | 1.50 | 1.50 | NR | 7 to 12 |
| Lam et al. 202198 | Spectacle (novel plus powered multiple segments) | −5.00 to −1.00 | Y | 1.50 | 1.50 | 20/20 | 8 to 13 |
| Mori et al. 202182 | Violet light transmitting spectacles | −4.40 to −1.50 | Y | 1.50 | 1.50 | NR | 6 to 12 |
| Moriche-Carretero et al. 2021113 | 0.01% atropine | −4.50 to −0.50 | Y | 1.50 | 1.00 | 20/30 | 5 to 11 |
| Prousali et al. 2022102 | Part-time single-vision spectacles | −6.00 to −0.50 | Y | 1.50 | 1.50 | 20/25 | 4 to 16 |
| Rappon et al. 202299 | Spectacles (two novel diffusion optics patterns) | −4.50 to −0.75 | Y | 1.25 | 1.50 | 20/25 | 6 to10 |
| Ruiz-Pomeda et al. 2021105 | SCL (concentric dual zone) | −4.00 to −0.75 | Y | 1.00 | 1.00 | 20/25 | 8 to 12 |
| Saxena et al. 2021114 | 0.01% atropine | −6.00 to −0.50 | Y | 1.50 | 1.00 | 20/40 | 6 to 14 |
| Shen et al. 2022106 | SCL (extended depth of focus) | −8.00 to −1.00 | Y | 1.75 | 2.00 | 20/25 | 9 to 14 |
| Wang et al. 2022115 | 0.02% or 0.01% atropine | −6.00 to −1.25 | Y | 2.00 | 1.00 | 20/25 | 6 to 14 |
| Weng et al. 2022117 | SCL (extended depth of focus and concentric dual zone) | −3.50 to −0.75 | Y | 0.75 | 0.75 | 20/32 | 7 to 13 |
| Yam et al. 2022116 | Atropine (0.01%, 0.025%, 0.05%) | −1.00 or more myopic refraction | Y | 2.50 | NR | NR | 4 to 12 |
| Yuan et al. 2021118 | ortho-k with 0.01% atropine | −4.00 to −1.00 | N | 1.50 | NR | 25/25 stated | 8 to 12 |
| Zhu et al. 2022100 | Customized PALs | −4.00 to −0.50 | Y | 1.50 | 1.00 | 20/20 | 7 to 14 |
Ast, astigmatism; Aniso, anisometropia; ETDRS, early treatment diabetic retinopathy study; N, no/none; NR, not reported; PAL, progessive addition lens; Y, yes.